The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
BIT Mining settles with DOJ and SEC to resolve FCPA violations, while former CEO faces bribery-related charges
November 21, 2024
News Alert
Son of former Comptroller General of Ecuador pleads guilty in Odebrecht bribery scandal
November 19, 2024
News Alert
Venezuela-based subsidiary of global telecommunications operator resolves FCPA investigation
November 13, 2024
News Alert